Kanjinti (Trastuzumab)

Trastuzumab binds to the extracellular domain of the HER2 receptor on cancer cells, blocking signaling pathways that drive tumor growth. It also recruits immune cells to destroy HER2‑expressing cells through antibody‑dependent cellular cytotoxicity, thereby reducing tumor proliferation.

The dosing regimen for Kanjinti is determined by the prescribing oncologist based on the patient’s body weight, indication and treatment protocol. It is administered intravenously under medical supervision, typically following a loading dose and subsequent maintenance infusions as outlined in clinical guidelines.

Safety of Kanjinti during pregnancy or lactation has not been established. The product is generally avoided in pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out. Consultation with a specialist is essential before any exposure.

To order Kanjinti, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Kanjinti is a biosimilar to the reference product Herceptin (trastuzumab). Clinical studies have shown comparable efficacy, safety and immunogenicity profiles. Choice between the two often depends on pricing, supply logistics and institutional preference, while therapeutic outcomes remain similar.

Kanjinti must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken. During transport, a validated cold‑chain system is required to maintain temperature stability.

Kanjinti is administered as an intravenous infusion. The initial loading dose is usually given over a longer period, followed by shorter maintenance infusions. Premedication such as antihistamines or corticosteroids may be used to reduce infusion‑related reactions, and the infusion is performed in a setting equipped for emergency management.

The most serious adverse events include cardiac toxicity, manifested as reduced left ventricular ejection fraction or heart failure, and severe infusion reactions such as anaphylaxis or bronchospasm. Regular cardiac monitoring and vigilant observation during infusions are essential to detect these risks early.

Kanjinti is contraindicated in patients with known hypersensitivity to trastuzumab or any of its excipients. It should also be avoided in individuals with uncontrolled cardiac disease, recent myocardial infarction, or those receiving concurrent anthracycline therapy due to heightened cardiotoxic risk.